Research Article

Genotype-Phenotype Characterization of Novel Variants in Six Italian Patients with Familial Exudative Vitreoretinopathy

Giancarlo Iarossi, Matteo Bertelli, Paolo Enrico Maltese, Elena Gusson, Giorgio Marchini, Alice Bruson, Sabrina Benedetti, Sabrina Volpetti, Gino Catena, Luca Buzzonetti, and Lucia Ziccardi

1Department of Ophthalmology, Bambino Gesù IRCCS Children’s Hospital, Rome, Italy
2MAGI-Human Medical Genetics Institute, Bolzano, Italy
3MAGI-Human Medical Genetics Institute, Rovereto, Italy
4Eye Clinic, Department of Neurosciences, Biomedicine and Movement, University and AOUI (Azienda Ospedaliera Universitaria Integrata) of Verona, Verona, Italy
5Dipartimento Anestesia e Rianimazione Materno Infantile, Ospedale San Filippo Neri, Rome, Italy
6“G.B. Bietti” Foundation, IRCCS, Rome, Italy

Correspondence should be addressed to Paolo Enrico Maltese; paolo.maltese@assomagi.org

Received 3 April 2017; Accepted 4 June 2017; Published 5 July 2017

Academic Editor: Naheed Khan

Copyright © 2017 Giancarlo Iarossi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Familial exudative vitreoretinopathy (FEVR) is a complex disorder characterized by incomplete development of the retinal vasculature. Here, we report the results obtained on the spectrum of genetic variations and correlated phenotypes found in a cohort of Italian FEVR patients. Eight probands (age range 7–19 years) were assessed by genetic analysis and comprehensive age-appropriate ophthalmic examination. Genetic testing investigated the genes most widely associated in literature with FEVR: FZD4, LRP5, TSPAN12, and NDP. Clinical and genetic evaluations were extended to relatives of probands positive to genetic testing. Six out of eight probands (75%) showed a genetic variation probably related to the phenotype. We identified four novel genetic variants, one variant already described in association with Norrie disease and one previously described linked to autosomal dominant FEVR. Pedigree analysis of patients led to the classification of four autosomal dominant cases of FEVR (caused by FZD4 and TSPAN12 variants) and two X-linked FEVR probands (NDP variants). None of the patients showed variants in the LRP5 gene. This study represents the largest cohort study in Italian FEVR patients. Our findings are in agreement with the previous literature confirming that FEVR is a clinically and genetically heterogeneous retinal disorder, even when it manifests in the same family.

1. Introduction

Familial exudative vitreoretinopathy (FEVR, OMIM 133780) is a complex disorder characterized by incomplete development of the retinal vasculature. Typical signs of this disorder include avascular areas in the peripheral retina detectable by fluorescein angiography due to abnormal congenital angiogenesis that can cause early-onset neovascularization, falciform folds, lipid exudation, and tractional retinal detachment [1, 2]. Insights into genetic causes of this disorder have emerged in the last few years. Four genes involved in the Norrin/β-catenin signaling pathway are linked to the disease: NDP, FZD4, LRP5, and TSPAN12, and are responsible for about 50% of FEVR cases [3].

Norrin/Frizzled signaling is known to be critical for retinal angiogenesis by controlling retinal vascular growth and architecture both in the developing eye and in adult vasculature; impairment of the signaling system has profound
**2. Materials and Methods**

Probands (age ranging from 7 to 19 years) and their families were examined in two different eye clinics: the Eye Clinic, Department of Neurosciences, Biomedicine and Movement, (University and Azienda Ospedaliera Universitaria Integrata of Verona, Italy) and the Department of Ophthalmology (Bambino Gesù IRCCS Children’s Hospital, Rome, Italy).

Probands and relatives underwent comprehensive age-appropriate ophthalmic examination, including best-corrected visual acuity (BCVA) measurement with the Early Treatment Diabetic Retinopathy Study (ETDRS) charts, expressed as a logarithm of the minimum angle of resolution (logMAR), slit-lamp biomicroscopy, indirect ophthalmoscopy with 15 D noncontact lens (Volk), fluorescein angiography or color fundus photos (obtained by RetCam in younger patients requiring examination under anesthesia and by Daytona wide-field retinography in compliant older subjects), optical coherence tomography (OCT), and full-field electroretinogram (ERG) recorded according to the ISCEV standards. Refractive errors ranged between +2 and −2 spherical equivalent. All examinations were performed at the referring clinic, and the results were collected at the end of the study.

Based on clinical data, each patient was classified according to the FEVR clinical staging system [16].

All patients received genetic counseling to explain the risks and benefits of genetic testing, and informed consent was obtained from their parents. The study followed the tenets of the Declaration of Helsinki.

Demographic details and information on personal and family medical history were recorded and used to determine the inheritance pattern and to draw pedigrees according to the recommendations of the National Society of Genetic Counselors [17] using the HaploPainter software [18].

Genetic testing was performed at MAGI’s Laboratories (MAGI - Human Medical Genetics Institute, Rovereto and Bolzano, Italy). Extracted DNA (Blood DNA Kit E.Z.N.A.; Omega Bio-Tek Inc., Norcross, GA, USA) underwent polymerase chain reaction (PCR) to amplify all coding regions and the intron/exon junctions of the FZD4 (OMIM *604579, NM_012193), LRP5 (OMIM *603506, NM_002335), TSPAN12 (OMIM *613138, NM_012338), and NDP (OMIM *300658, NM_000266) genes. Purified products were sequenced with a Beckman Coulter CEQ 8000 sequencer (Beckmann Coulter, Milano, Italy). All laboratory protocols are available on request.

The electropherograms of amplified fragments were analyzed using ChromasPro 1.5 (Technelysium Pty. Ltd., Australia) and Sequencher 5.0 (Gene Codes®; Ann Arbor, MI, USA) software and compared to GenBank reference sequences with the Basic Local Alignment Search Tool (BLAST; http://blast.ncbi.nlm.nih.gov). All detected genetic variations were sequenced bidirectionally at least twice for confirmation.

To identify variants previously reported as pathogenic, the Human Gene Mutation Database (HGMD; http://www.biobase-international.com/product/hgmd) was consulted. To evaluate Minor Allele Frequencies (MAF) in populations, all discovered genetic variants were also looked up in the public database of single-nucleotide variants (dbSNP; www.ncbi.nlm.nih.gov/SNP/) and the Exome Variant Server (EVS; http://evs.gs.washington.edu/EVS/) database. New nucleotide variations were assessed for pathogenicity using the PolyPhen 2 algorithm (Polyorphism Phenotyping v2; http://genetics.bwh.harvard.edu/pph2) considering the HumVar-trained model [19], the SIFT algorithm (Sorting Intolerant From Tolerant; http://sift.bii.a-star.edu.sg/) [20] and MutationTaster (http://www.mutationtaster.org) [21]. Defective splicing was evaluated using the Human Splicing Finder online software version 3 (http://www.umd.be/HSF3/HSF.html) [22]. When possible, wild-type amino acid properties were compared with the variations (http://www.russelllab.org/aas/aas.html) [23].

Variants were reported following the current nomenclature as described by the Human Genome Variation Society (http://www.hgvs.org/mutnomen/recs.html).

To classify sequence variants, we used the criteria by the American College of Medical Genetics and Genomics (ACMG) Standards and Guidelines [24].
3. Results

Genetic testing revealed that 6 out of 8 (75%) probands had a genetic variation in one of the genes analyzed. Consequently, a segregation study was performed by extending clinical and genetic analyses to a total of 10 relatives.

Pedigree analysis of patients with inherited forms of the disease led to the classification of four autosomal dominant cases of FEVR (FZD4 and TSPAN12 variations) and one X-linked FEVR proband (NDP variation) (see Table 1).

None of the patients showed variations in the LRP5 gene. No MAF are reported for the identified variants in all the questioned database.

In silico evaluation of genetic variations identified in FEVR families; genotype heterozygous (Het), hemizygous (Hemi); SIFT score system: tolerated (T), deleterious (D); Polyphen 2 score system: benign (B), possibly damaging (PoD), probably damaging (PrD); Mutation Taster score system: polymorphism (P), disease causing (DC); VUS: variation of unknown significance.

3.1. Family 1. The male proband (II:1) came to our attention only recently at the age of nine years. Previously performed fluorescein angiography with RetCam showed a large avascular area in the peripheral retina without signs of neovascularization or peripheral exudation. The LE presented a falciform retinal fold anchored to the temporal retinal sector without signs of peripheral exudation (FEVR stage 3A). *Documented clinical evaluation; E+ and E−, positive and negative to genetic test, respectively; RE, right eye; LE, left eye.
and left eyes, respectively. Clinical conditions are currently stable, and visual acuity is 0.0 LogMAR in the right eye and 1.0 LogMAR in the left eye. It was not possible to perform a complete clinical examination on the proband’s mother (I:2) and father (I:1). The last fundus examination of the mother showed normal retinal features; however, we could not proceed with any instrumental examinations due to the patient’s refusal to undergo further testing.

Genetic testing revealed that the proband and his mother were heterozygous for the new p.(Gln93∗) variation in the FZD4 gene.

3.2. Family 2. This male proband (II:1) presented exotropia of the right eye at the age of 2 years. Ophthalmological examination under general anaesthesia showed inoperable falciform fold in the right eye and vascular alterations in the left eye. The patient was diagnosed with stage 3 and stage 2 FEVR in the right and left eyes, respectively. At the age of 3 years, scleral buckle, cryo treatment, and laser treatment for retinal detachment were performed in the right eye and laser treatment of the retinal periphery in the left eye. After a period of clinical stationary conditions, at the age of 5 years, the patient required further laser treatment in the left eye due to reactivation of the disease. Visual acuity is currently 0.1 and 0.2 LogMAR in the right and left eye, respectively.

The fundus examination of the father (I:1) showed slight abnormalities of the peripheral retina suggesting a condition of FEVR healthy carrier.

Genetic testing revealed that the proband and his father were heterozygous for a variation of the gene FZD4, p.(Cys181Tyr); the mother was not assessed. Figure 2 shows the autosomal dominant transmission of the variant p.(Cys181Tyr) in the FZD4 gene and the clinical features of the family.

3.3. Family 3. The proband (II:2), a 19 y/o male, presented disease onset at the age of 13 years, with bilateral exudative retinopathy associated with slight visual acuity reduction. In detail, the patient showed exotropia of the right eye from early infancy and visual acuity of 0.1 LogMAR in both eyes. At the age of 13 years, he suffered a sharp decline in visual acuity (0.3 LogMAR in both eyes), associated with hard retinal exudates in the temporal periphery at the fundus examination. Based on the presence of posterior hyaloid contraction, macular edema, macular dragging, and accentuated peripheral exudation in both eyes, bilateral stage 4A FEVR was postulated. A few months after diagnosis, the patient underwent vitrectomy, cryo treatment, and injection of humanized anti-VEGF monoclonal antibody (Bevacizumab) in both eyes.

The patient was monitored every 6 months for the following three years by visual acuity measurements, OCT scans, and fluorescein angiographies. Since the peripheral exudations remained active, with angiographic evidence of leakage, the patient underwent multiple sessions of Argon laser, cryo treatment, and Bevacizumab injections (Figure 3). At the time of this report, visual acuity was.
0.1 LogMAR in both eyes without signs of pathological activity for the last three years.

The proband’s father (I:1) and sister (II:1) are healthy, whereas his mother (I:2), 52 years old, was diagnosed with stage 2B FEVR and related mild macular edema at the age of 46. Both eyes were treated with Argon laser, and her current visual acuity is 0.0 LogMAR in both eyes (Figure 3).

Autosomal dominant inheritance was suspected before genetic evaluation (Figure 3). Genetic evaluation showed that the proband and his mother were heterozygous for a new p.(Cys204Phe) variant in the FZD4 gene, while the father and the sister were negative to the test.

### 3.4. Family 4.

This 7 y/o male proband (II:2) came to our attention at the age of one year presenting congenital sensory nystagmus. Ophthalmological examination under sedation revealed the presence of a falciform fold arising from the optic nerve head, with partial traction on the surrounding retina. Stage 3A FEVR of the proband’s older brother (II:1) is shown in the color fundus photograph from his LE. Macular OCT images of proband’s father and mother are also shown in upper left and upper right quadrants of figure, respectively. The mother’s exam shows a slight reduction of macular thickness.

**Figure 3:** Pedigree and ocular features of family 3. Daytona wide-field color fundus photos and OCT scans of the proband (II:2) at the age of 19 years with bilateral exudative manifestation of FEVR stage 4A. Peripheral retinal signs of cryo treatment and Argon laser barrage, performed after evidence of fluorangiographic leakage, can be seen in the inferior temporal sectors in both eyes. Daytona wide-field color fundus photographs of the proband’s mother (I:2), showing treatment with Argon laser in the retinal periphery of both eyes. Angiograms from the posterior pole and from the midperiphery do not present signs of disease’s activity after laser treatment. *Documented clinical evaluation; E+ and E−, positive and negative to genetic test, respectively; RE, right eye; LE, left eye.

**Figure 4:** Pedigree and ocular features of family 4. Fluorescein angiograms by RetCam from the 7 y/o male proband (II:2) of family 4, showing FEVR stage 2B with slight optic nerve pallor, areas of chorioretinal atrophy due to previous laser treatment and a persisting small area of leakage in the peripheral retina of the RE. Color fundus photographs by RetCam of the LE with FEVR stage 3B clearly show the presence of a falciform fold arising from the optic nerve head, with partial traction on the surrounding retina. Stage 3A FEVR of the proband’s father and mother are also shown in upper left and upper right quadrants of figure, respectively. The mother’s exam shows a slight reduction of macular thickness.

*Documented clinical evaluation; E+ and E−, positive and negative to genetic test, respectively; ● obligate carrier; RE, right eye; LE, left eye.
were stable. At the orthoptic examination, torticollis due to nystagmus with the face rotated to the right to favour fixation of the right eye in adduction was found. Visual acuity was 0.1 LogMAR in the left eye and 0.4 LogMAR in the right eye, respectively.

The proband’s 10 y/o brother (II:1) was diagnosed with bilateral retinal dystrophy and falciform retinal fold at the age of three, suggesting a stage 3A FEVR (Figure 4). The left eye also showed a slight posterior opacity of the lens while the ectopic pupil was visible in the right eye. Visual acuity was lower than 0.1 LogMAR in both eyes.

The children’s parents have visual acuities of 0.0 LogMAR in both eyes. The father’s fundus was normal, whereas the mother showed slight mottling of the retinal pigmented epithelium, more evident at the periphery. Full-field electroretinography was within normal limits in the parents, though the mother’s scotopic ERG responses were borderline and her macular OCT scans showed a reduction of foveal thickness suggesting a condition of asymptomatic carrier (Figure 4).

Genetic testing revealed the p.(Arg121Gln) variant in the NDP gene, already associated in literature with Norrie disease (MIM *310600) [25] (Figure 4).

3.5. Family 5. The 3 y/o male proband (II:1) came to our attention at the age of four months presenting leukocoria in the right eye. The fundus examination under sedation showed an inoperable macula-involving retinal detachment with subretinal exudate in the right eye and peripheral exudation with vascular abnormalities in the left eye. A fluorescein angiography exam performed with RetCam showed peripheral ischemic areas with leakage mainly in temporal and inferior peripheral retina which required laser treatment in the left eye. Consequently, stages 4B and 1B FEVR were diagnosed in the right and left eyes, respectively. At subsequent examinations, the right eye progressed into a closed funnel total retinal detachment whereas the left eye was stable. The child’s father could not be examined while the mother showed a visual acuity of 0.0 LogMAR in both eyes. Her fundus was normal presenting only a slight mottling of the retinal pigmented epithelium in the peripheral retina. Full-field electoretinography and macular OCT scans were within normal limits in both eyes. (Figure 5). Genetic testing revealed that the proband and his mother (I:2) have a p.(Ala105Phe) variation in the NDP gene.

3.6. Family 6. The 7 y/o male proband (II:1) was periodically monitored for visual loss due to FEVR since the age of one. The fundus examination under sedation showed a falciform retinal fold arising from the optic nerve head, involving the macula and anchored in the temporal periphery in his left eye (Figure 6). No exudation was evident near the fold or the temporal or nasal periphery. Based on aforementioned clinical data, stage 3A FEVR was postulated. No significant changes were found at the subsequent follow-up. The ophthalmological examination performed at the age of three showed residual visual acuity of 1.0 LogMAR in both eyes. The proband’s father did not present any sign of ocular pathology while the mother was diagnosed with stage 1 FEVR in both eyes.

Genetic testing revealed the heterozygous IVS2 c.67-2A>G variant in the TSPAN12 gene, and the same variant was found in the proband’s mother (I:2), thus configuring an autosomal dominant transmission (Figure 6).

4. Discussion

In the present work, we reported the clinical findings and the genetic analysis from a cohort of 6 unrelated Italian
families made up of 6 probands and 10 family members, thus presenting the results from the largest cohort of Italian FEVR families and data from four novel genetic variants linked to FEVR.

Retinal vascularization during eye development and maintenance of its normal architecture are processes finely orchestrated by the Norrin/β-catenin signaling pathway. This pathway is distinguished from the Wingless (Wnts) signaling pathways, which include a large family of ligands and are involved in many cell processes, and is specific for the development and maintenance of the retinal vasculature. The bond in NDP is in fact highly specific for the receptor complex FZD4-LRP5 [26] while TSPAN12 is required for FZD4/β-catenin signaling induced by Norrin. Moreover, TSPAN12 expression is restricted to the vasculature within the retina [27].

Aberrations and malfunctioning of this signaling system affect the development of the retinal vasculature, and this translates into a variety of eye diseases such as Norrie disease, FEVR, and retinopathy of prematurity [5, 6, 28]. All these disorders are clinically and genetically heterogeneous. Nucleotide alterations in the genes’ coding for fundamental components of this signaling pathway, such as NDP growth factor (NDP gene), FZD4 receptor (FZD4 gene), LRP5 coreceptor (LRP5 gene), and tetraspanins (TSPAN12 gene) are described as associated with different pathological phenotypes, ranging from mild to severe, even in the same family, or with clinically indistinguishable patterns caused by variations in different genes.

Our genetic testing investigated on the four genes most widely associated in literature with FEVR: NDP, FDZ4, LRP5, and TSPAN12 [3].

In the present report, families 1, 2, and 3 had three different heterozygous variants in the FZD4 gene. FZD4 codes for FZD4, a member of the Frizzled family of seven-transmembrane Wnt-binding receptors. The binding of Wnt or Norrin ligands with FZD4 in conjunction with LRP5 coreceptors results in the activation of canonical β-catenin-dependent signaling. The N-terminal extracellular cysteine-rich domain (CRD), conserved among Frizzled family members, is necessary for binding to ligands [29].

The p.(Gln93*) variation in the FZD4 gene found in family 1 introduces a premature stop codon, and therefore, it is predicted to be pathogenic.

In families 2 and 3, the two variants are found in the extracellular N-terminal domain of the receptor, in amino acid positions 181 and 204, respectively. Both are presumably downstream of the CRD required for ligand binding, according to Smallwood et al. (i.e., the 114-amino acid region extending from the first to the tenth conserved CRD cysteine) [30], but their importance is relevant because variations in both codons, associated with a pathological phenotype, have already been described in literature and both can therefore be considered mutational hot spots.

The variant p.(Cys181Tyr) has already been described by Drenser et al. and associated with autosomal dominant FEVR [31]. The author concluded that this cysteine residue is not known to form an intracellular disulphide bond; it is nevertheless the 11th of 13 cysteine residues that are conserved in vertebrates and may be required for receptor dimerization [32], a function that may be relevant to the mechanism of Wnt binding and signaling [33]. In family 2, the healthy father, who carries this variant, showed a subclinical phenotype (stage 1 FEVR). It is well known that variations in this gene have complete (100%) penetrance but variable expression: members of the same family may have the same variant and show differences in severities of the disorder or may have retinal changes detectable only by diagnostic tools such as fluorescein angiography. Moreover, the disease phenotype in this family showed interesting aspects of FEVR pathology: (1) an asymmetrical impairment of the retina, (2) the importance of a follow-up in patients by fluorescein angiography, even in case of a normal (left eye) posterior pole, (3) the necessity of a different treatment approach for the lesions depending on the stages of the disease, and (4) the evidence that inactive lesions may later on constitute an ophthalmological emergency (retinal detachment in the right eye).

Similarly, variations in the 204 codon, as we found in family 3, have already been associated with autosomal dominant FEVR in two reports, one describing the amino acid
change p.(Cys204Arg) [34] and the other, the p.(Cys204Tyr) change [35].

A functional study by Zhang et al. showed that FZD4 binding to NDP is disrupted by Cys204Arg, suggesting that the CRD may be beyond the previously predicted region, as described by Smallwood et al. [30], or that NDP binding to FZD4 requires the CRD plus additional residues, C-terminal to the CRD [29]. The autosomal dominant feature of FZD4 variants could be due either to haploinsufficiency or to a dominant-negative effect, as previous findings suggest [36].

In family 4, the proband and the brother are affected by an X-linked form of FEVR due to a variant in the NDP gene. NDP is a protein ligand not belonging to the Wnt family which recognises and binds with high affinity and specificity to the CRD of FZD4 (and not to CRDs of the other 14 mammalian Frizzled and secreted Frizzled-related proteins) [30] and activates the canonical signaling pathway [26].

The p.(Arg121Gln) variant in the NDP gene has already been reported in literature, and the amino acid residue 121 seems to be a mutational hot spot. Indeed, the same amino acid change from arginine to glutamine has been associated with Norrie disease [25]; however, variants in the same codon, specifically p.(Arg121Gly) [37] and p.(Arg121Trp) [38], have been associated both with Norrie disease and with X-linked FEVR, that is, the p.(Arg121Leu) [39] and p.(Arg121Trp) variants [40].

Similarly, the p.(Ala105Phe) found in family 5 lies in a mutational hot spot since two other variants in the same codon, namely, the p.(Ala105Thr) and the p.(Ala105Glu), were described as associated with Norrie Disease [13] and FEVR [41], respectively.

Both variants found in families 4 and 5 are located in the C-terminal end of the Norrie protein, probably affecting the secondary structure and function of the protein.

Norrie disease is a complex disorder in which blindness in early childhood may be accompanied by sensorineural deafness and progressive mental retardation, inherited by X-linked recessive transmission. Heterozygous carriers rarely manifest clinical features of the disorder, though some cases have been described [42, 43]. The absence of a syndromic pattern with extracocular manifestations and preservation of some vision suggested a diagnosis of FEVR rather than Norrie disease, in both families.

Furthermore, the description of the same variant in subjects with different clinical patterns may indicate the involvement of other factors that might modify the phenotype.

In family 6, the proband and his mother harbour the same heterozygous variant IVS2 c.67-2A>G in the TSPAN12 gene. TSPAN12 is a member of the tetraspanin superfamily characterized by four transmembrane domains. It is a key component of the NDP-FZD4-LRP5 signaling complex that cooperatively promotes multimerization of FZD4 and its associated proteins to elicit physiological levels of signaling [27]. Both dominant and recessive variants in TSPAN12 have been described in FEVR [8, 11].

The novel variant reported here is predicted to interfere with the consensus sequence for the splice acceptor site of intron 2, as confirmed using HSF.

Poulter et al. described the c.67-1G>C variant in both homozygous and heterozygous states in two FEVR Indian cousins; the c.67-1G>G splice variant causes exon 3 deletion, resulting in a frameshift and a premature termination codon (p.Leu23GlyfsX66) [11]. Considering that the c.67-2A>G variant reported in our work involves the same acceptor splicing site, it is reasonable to expect the same pathogenetic effect.

The severe clinical expression of the disease observed in our patient is consistent with previous studies where variations in TSPAN12 gene are reported to be associated with very severe disease phenotypes [11, 27].

5. Conclusions

To our knowledge, this is the largest cohort study of Italian FEVR patients. In the present retrospective study involving different clinical sites, the probands and their family members were clinically examined and identified by standard diagnostic tests, albeit performed by different operators; this, together with the limited observed population, impedes critical analysis of the phenotypic differences associated with the variations in different genes of the Norrin/Frizzled signaling pathway in our group of FEVR patients. Variations of the analyzed genes were found in 6 out of 8 (75%) patients, and four novel variants responsible for the phenotype were identified.

The variants in the FZD4 gene found in families 1, 2, and 3 were associated with the mildest phenotype: in families 1 and 2, FEVR manifested with late onset and vision was preserved in the affected family members, whereas in family 3, patients showed earlier disease onset with relatively preserved vision in the proband and mild loss of visual acuity in the mother.

The X-linked FEVR variants involving the NDP gene in families 4 and 5 are considered severe because they determine an early onset of the disease with relevant retinal alterations. Minimal signs of retinal abnormalities were detected also in the mother of the two affected children who carried the same variant in family 4, while in family 5, the variant exerted no effects in the proband’s mother.

The variant in the TSPAN12 gene in family 6 caused a very severe phenotype that manifested from the first months of life with almost complete vision loss.

Our results are in agreement with the previously described literature confirming that familial exudative vitreoretinopathy presents a penetrance close to 100% [16] but is clinically and genetically heterogeneous [12], even in the same family [44]. Indeed, the two new heterozygous variants found in the FZD4 gene and those in NDP and TSPAN12 genes, respectively, were correlated with variable phenotypical presentation ranging from relatively mild to severe anatomical and functional impairment. Severity of phenotype was dependent on gene involvement and site of nucleotide variations.

Analysis of new genes recently found to be associated with FEVR will make it possible to improve the understanding of the pathogenesis of the disease.
Conflicts of Interest

Each author states that he/she has no proprietary interest in the development or marketing of the instruments used in the present study. The authors declare that they do not have any conflict of interest.

Authors’ Contributions

Giancarlo Iarossi, Paolo Enrico Maltese, and Lucia Ziccardi contributed equally to this study.

Acknowledgments

The contribution by Fondazione Bietti in this paper was supported by the Ministry of Health and Fondazione Roma. The authors are grateful to Helen Ampt for revising the manuscript.

References

[1] C. E. Van Nouhuys, "Juvenile retinal detachment as a complication of familial exudative vitreoretinopathy," Fortschrritte der Ophthalmologie, vol. 86, pp. 221–223, 1989.
[2] W. E. Benson, "Familial exudative vitreoretinopathy," Transactions of the American Ophthalmological Society, vol. 93, pp. 473–521, 1995.
[3] R. W. Collin, K. Nikopoulos, M. Dona et al., “ZNF408 is mutated in familial exudative vitreoretinopathy and is crucial for the development of zebrafish retinal vasculature,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, pp. 9856–9861, 2013.
[4] X. Ye, Y. Wang, H. Cahill et al., "Norrin, frizzled-4, and Lrp5 signaling in endothelial cells control a genetic program for retinal vascularization," Cell, vol. 139, pp. 285–298, 2009.
[5] T. N. Masckauchán and J. Kitajewski, "Wnt/frizzled signaling in the vasculature: new angiogenic factors in sight," Physiology (Bethesda), vol. 21, pp. 181–188, 2006.
[6] J. Robitaille, M. L. MacDonald, A. Kaykas et al., "Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy," Nature Genetics, vol. 32, pp. 326–330, 2002.
[7] C. Toomes, H. M. Bottomley, R. M. Jackson et al., "Mutations in LRPS or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q," American Journal of Human Genetics, vol. 74, pp. 721–730, 2004.
[8] K. Nikopoulos, C. Gilissen, A. Hoischen et al., "Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy," American Journal of Human Genetics, vol. 86, pp. 240–247, 2010.
[9] B. S. Shastry and M. T. Trese, "Familial exudative vitreoretinopathy: further evidence for genetic heterogeneity," American Journal of Medical Genetics, vol. 69, pp. 217–218, 1997.
[10] B. S. Shastry, J. F. Heijtmancik, and M. T. Trese, "Identification of novel missense mutations in the Norrie disease gene associated with one X-linked and four sporadic cases of familial exudative vitreoretinopathy," Human Mutation, vol. 9, pp. 396–401, 1997.
[11] J. A. Poult, A. E. Davidson, M. Ali et al., "Recessive mutations in TSPAN12 cause retinal dysplasia and severe familial exudative vitreoretinopathy (FEVR)," Investigative Ophthalmology & Visual Science, vol. 53, pp. 2873–2879, 2012.
[12] F. N. Boonstra, C. E. van Nouhuys, J. Schuil et al., "Clinical and molecular evaluation of probands and family members with familial exudative vitreoretinopathy," Investigative Ophthalmology & Visual Science, vol. 50, pp. 4379–4385, 2009.
[13] I. Torrente, M. Mangino, M. Gennarelli et al., "Two new missense mutations (A105T and C110G) in the norrin gene in two Italian families with Norrie disease and familial exudative vitreoretinopathy," American Journal of Medical Genetics, vol. 72, pp. 242–244, 1997.
[14] G. de Crecchio, F. Simonelli, G. Nunziata et al., "Autosomal recessive familial exudative vitreoretinopathy: evidence for genetic heterogeneity," Clinical Genetics, vol. 54, pp. 315–320, 1998.
[15] M. Savarese, E. Spinelli, F. Gandolfo et al., "Familial exudative vitreoretinopathy caused by a homozygous mutation in TSPAN12 in a cystic fibrosis infant," Ophthalmic Genetics, vol. 35, pp. 184–186, 2014.
[16] A. H. Kashani, K. T. Brown, E. Chang, K. A. Dresner, A. Capone, and M. T. Trese, "Diversity of retinal vascular anomalies in patients with familial exudative vitreoretinopathy," Ophthalmology, vol. 121, pp. 2220–2227, 2014.
[17] R. L. Bennett, K. S. French, R. G. Resta, and D. L. Doyle, "Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors," Journal of Genetic Counseling, vol. 17, pp. 424–433, 2008.
[18] H. Thiele and P. Nürnberg, "HaploPainter: a tool for drawing pedigrees with complex haplotypes," Bioinformatics, vol. 21, pp. 1730–1732, 2005.
[19] I. A. Adzhubei, S. Schmidt, L. Peshkin et al., "A method and server for predicting damaging missense mutations," Nature Methods, vol. 7, pp. 248–249, 2010.
[20] P. Kumar, S. Henikoff, and P. C. Ng, "Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm," Nature Protocols, vol. 4, pp. 1073–1081, 2009.
[21] J. M. Schwarz, D. N. Cooper, M. Schuelke, and D. Seelow, "MutationTaster2: mutation prediction for the deep-sequencing age," Nature Methods, vol. 11, pp. 361–362, 2014.
[22] F. O. Desmet, D. Hamroun, M. Lalande, G. Collod-Béroud, M. Claustres, and C. Béroud, "Human Splicing Finder: an online bioinformatics tool to predict splicing signals," Nucleic Acids Research, vol. 37, article e67, 2009.
[23] M. J. Betts and R. B. Russell, "Amino acid properties and consequences of substitutions," in Bioinformatics for Geneticists, M. R. Barnes and I. C. Gray, Eds., pp. 289–316, John Wiley & Sons, Ltd, Chichester, UK, 2003.
[24] S. Richards, N. Aziz, S. Bale et al., "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology," Genetics in Medicine, vol. 17, no. 5, pp. 405–424, 2015.
[25] J. J. Fuentes, V. Volpini, F. Fernández-Toral, E. Coto, and X. Estivill, "Identification of two new missense mutations (K58N and R121Q) in the Norrie disease (ND) gene in two Spanish families," Human Molecular Genetics, vol. 2, pp. 1953–1955, 1993.
[26] Q. Xu, Y. Wang, A. Daboub et al., "Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a
high-affinity ligand-receptor pair,” Cell, vol. 116, pp. 883–895, 2004.

[27] H. J. Junge, S. Yang, J. B. Burton et al., "TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling," Cell, vol. 139, pp. 299–311, 2009.

[28] R. F. Gariano and T. W. Gardner, "Retinal angiogenesis in development and disease," Nature, vol. 438, pp. 960–966, 2005.

[29] K. Zhang, Y. Harada, X. Wei et al., "An essential role of the cysteine-rich domain of FZD4 in Norrin/Wnt signaling and familial exudative vitreoretinopathy," The Journal of Biological Chemistry, vol. 286, pp. 10210–10215, 2011.

[30] P. M. Smallwood, J. Williams, Q. Xu, D. J. Leahy, and J. Nathans, "Mutational analysis of Norrin-Frizzled4 recognition," The Journal of Biological Chemistry, vol. 282, pp. 4057–4068, 2007.

[31] K. A. Drenser, W. Dailey, A. Vinekar, K. Dalal, A. Capone Jr., and M. T. Trese, "Clinical presentation and genetic correlation of patients with mutations affecting the FZD4 gene," Archives of Ophthalmology, vol. 127, pp. 1649–1654, 2009.

[32] S. Omoto, T. Hayashi, K. Kitahara, T. Takeuchi, and Y. Ueoka, "Autosomal dominant familial exudative vitreoretinopathy in two Japanese families with FZD4 mutations (H69Y and C181R)," Ophthalmic Genetics, vol. 25, pp. 81–90, 2004.

[33] C. E. Dann, J. C. Hsieh, A. Rattner, D. Sharma, J. Nathans, and D. J. Leahy, "Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains," Nature, vol. 412, pp. 86–90, 2001.

[34] J. Nallathambi, D. Shukla, A. Rajendran, P. Namperumalsamy, R. Muthulakshmi, and P. Sundaresan, "Identification of novel FZD4 mutations in Indian patients with familial exudative vitreoretinopathy," Molecular Vision, vol. 12, pp. 1086–1092, 2006.

[35] K. Nikopoulos, H. Venselaar, R. W. Collin et al., "Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRP5, and NDP," Human Mutation, vol. 31, pp. 656–666, 2010.

[36] A. Kaykas, J. Yang-Snyder, M. Héroux, K. V. Shah, M. Bouvier, and R. T. Moon, "Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization," Nature Cell Biology, vol. 6, pp. 52–58, 2004.

[37] D. Zhu and I. Hussel-Maumanee, "Mutation analysis of the Norrie disease gene in eleven families," Investigative Ophthalmology & Visual Science, vol. 35(Supplement), p. 1265, 1994.

[38] A. Meindl, B. Lorenz, H. Achatz, H. Hellebrand, P. Schmitz-Valckenberg, and T. Meitinger, "Missense mutations in the NDP gene in patients with a less severe course of Norrie disease," Human Molecular Genetics, vol. 4, pp. 489–490, 1995.

[39] K. Johnson, H. A. Mintz-Hittner, Y. P. Conley, and R. E. Ferrell, "X-linked exudative vitreoretinopathy caused by an arginine to leucine substitution (R121L) in the Norrie disease protein," Clinical Genetics, vol. 50, pp. 113–115, 1996.

[40] S. Fuchs, U. Kellner, H. Wedemann, and A. Gal, "Missense mutation (Arg121Trp) in the Norrie disease gene associated with x-linked exudative vitreoretinopathy," Human Mutation, vol. 6, pp. 257–259, 1995.

[41] J. Salvó, V. Lyubasyuk, M. Xu et al., "Next-generation sequencing and novel variant determination in a cohort of 92 familial exudative vitreoretinopathy patients," Investigative Ophthalmology & Visual Science, vol. 56, no. 3, pp. 1937–1946, 2013.

[42] P. Lin, S. P. Shankar, J. Duncan, A. Slavotinek, E. M. Stone, and T. Rutar, "Retinal vascular abnormalities and dragged maculae in a carrier with a new NDP mutation (c.268delC) that caused severe Norrie disease in the proband," Journal of AAPOS, vol. 14, pp. 93–96, 2010.

[43] T. Parzefall, T. Lucas, M. Ritter et al., "A novel missense NDP mutation [p.(Cys93Arg)] with a manifesting carrier in an Austrian family with Norrie disease," Audiology & Neuro-Otology, vol. 19, pp. 203–229, 2014.

[44] R. R. Ober, A. C. Bird, A. M. Hamilton, and K. Sehmi, "Autosomal dominant exudative vitreoretinopathy," The British Journal of Ophthalmology, vol. 64, no. 2, pp. 112–120, 1980.